Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Wootton

Gastroenterology Norfolk, VA Medical Doctor

NPI 1750366761 CMS profile 261376

885 Kempsville Rd, Suite 114, Norfolk, VA 23502

Open in the dashboard

General payments

$5,804

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,541 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Frank Wootton of Norfolk, VA is reported in the CMS Open Payments database as having received $5,804 across 284 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,541 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,732 76
2024 General $1,466 69
2023 General $976 48
2022 General $421 21
2020 General $189 12
2019 General $1,021 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Wootton
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Frank Wootton were reported at $1,732. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Frank Wootton Gastroenterology median Middle half National median
2019 $1,021 $417 $126–$1,100 $163
2020 $189 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $421 $448 $129–$1,270 $149
2023 $976 $533 $150–$1,390 $160
2024 $1,466 $605 $160–$1,606 $164
2025 $1,732 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,281 70 payments
  2. Gilead Sciences, Inc. $619 30 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $493 30 payments
  4. Janssen Biotech, Inc. $429 20 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $426 21 payments
  6. Regeneron Healthcare Solutions, Inc. $307 13 payments
  7. Celltrion USA Inc. $222 8 payments
  8. Ardelyx, Inc. $185 8 payments
  9. Medtronic, Inc. $175 6 payments
  10. QOL Medical, LLC $162 8 payments
  11. Other $1,506 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,752 282 payments
  2. Education $52 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $507 23 payments
  2. STELARA $485 18 payments
  3. ENTYVIO $368 20 payments
  4. XIFAXAN $366 17 payments
  5. HUMIRA $262 17 payments
  6. SKYRIZI Immunology $243 11 payments
  7. SKYRIZI Immunology $239 11 payments
  8. CREON $235 13 payments
  9. DUPIXENT $226 10 payments
  10. LINZESS $205 10 payments
  11. Other $2,931 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

866

Median for Gastroenterology: 569

Drug cost

$265,296

Median for Gastroenterology: $104,976

Branded share of claims

54.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Pen Adalimumab Brand 13 $92,279
Xifaxan Rifaximin Brand 16 $59,850
Linzess Linaclotide Brand 60 $53,864
Mesalamine Generic 54 $26,860
Colesevelam Hcl Generic 33 $8,955
Mesalamine Dr Mesalamine Brand 12 $3,043
Budesonide Ec Budesonide Brand 12 $3,024
Omeprazole Generic 171 $2,675
Budesonide Dr Budesonide Brand 20 $2,460
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 13 $2,073

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$197,893

Medicare's payments for the services billed

Medicare patients

857

Average age 74

Services billed

1,348

461 women, 396 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 38%
Ischemic heart disease 30%
Depression 27%
Chronic kidney disease 26%
Heart failure 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $138
$138 16 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $128
$128 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $109
$109 — —
STELARA
  • Janssen Biotech, Inc. $107
$107 — —
RINVOQ
  • AbbVie, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record